羟氯喹治疗原发性进展型多发性硬化
这项单臂II期无效性试验评估口服羟氯喹200mg每日两次治疗18个月对原发性进展型多发性硬化的效果。研究排除增强病灶者,主要终点为6至18个月间定时25英尺步行恶化≥20%。35例中仅8例恶化,达到主要终点,提示羟氯喹与残疾恶化减少相关且耐受性良好。
要点
- 羟氯喹200mg每日两次治疗18个月,35例中仅8例出现步行恶化≥20%。
- 研究达到主要终点,提示羟氯喹可能减少原发性进展型多发性硬化残疾恶化。
- 羟氯喹总体耐受良好,82%出现不良事件,12%出现严重不良事件。
核心结论
- 羟氯喹治疗与原发性进展型多发性硬化患者残疾恶化减少相关,是值得进一步随机对照试验研究的候选治疗。
研究设计与样本
- 单臂II期无效性试验,口服羟氯喹200mg每日两次,疗程18个月。
- 排除筛查MRI上存在对比增强病灶的参与者,以研究无 overt 局灶性炎症时的残疾恶化。
- 采用Simon两阶段设计,零假设为40%队列恶化,单侧备择假设为20%,5%一类错误率和80%把握度。
主要发现
- 主要终点为6至18个月随访间定时25英尺步行恶化≥20%。
- 35例参与者中仅8例在6至18个月间恶化,研究达到主要终点。
- 不良事件发生率82%,严重不良事件发生率12%,所有严重不良事件均不太可能与羟氯喹使用相关。
关键数值与推荐
- 基于原始试验数据,预期40%队列会恶化;若35例中少于10例出现临床显著恶化则判定羟氯喹治疗成功。
- 实际35例中8例恶化,满足成功标准。
- 严重不良事件发生率12%,均不太可能与羟氯喹相关。
临床怎么用
- 对于无对比增强病灶的原发性进展型多发性硬化患者,羟氯喹200mg每日两次可能减少残疾恶化。
- 治疗期间需监测不良事件,严重不良事件发生率12%但均不太可能与药物相关。
局限性
- 单臂设计,无安慰剂对照,结论需随机对照试验进一步验证。
- 样本量较小,共35例参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Primary progressive multiple sclerosis (PPMS) does not respond well to immunomodulatory or immunosuppressive treatment. Chronic activation of microglia has been implicated in the pathophysiology of PPMS. The antimalarial drug hydroxychloroquine (HCQ) reduces the activity of human microglia and has neuroprotective effects in vitro. METHODS: We conducted a single-arm, phase II futility trial of 200 mg oral HCQ twice daily for 18 months. In an effort to investigate disability worsening in the absence of overt focal inflammation, we excluded participants with contrast enhancing lesions on a screening magnetic resonance imaging (MRI). The primary end point was ≥20% worsening on the timed 25-foot walk measured between 6 and 18 months of follow-up. RESULTS: Based on original trial data, 40% of the cohort were expected to worsen. We used a Simon 2-stage design to compare a null hypothesis of 40% of the cohort worsening against the one-sided alternative of 20%. Using a 5% type 1 error rate and 80% power, HCQ treatment would be deemed successful if fewer than 10 of 35 participants experienced clinically significant worsening. The study met its primary end point, as only 8 of 35 participants worsened between 6 and 18 months. HCQ was overall well-tolerated, with adverse events in 82% and serious adverse events in 12% of participants. All serious adverse events were unlikely related to HCQ use. INTERPRETATION: HCQ treatment was associated with reduced disability worsening in people with PPMS. HCQ is a promising treatment candidate in PPMS and should be investigated further in randomized controlled clinical trials. ANN NEUROL 2021;90:940-948.
引用
- Koch MW, Kaur S, Sage K, et al. Hydroxychloroquine for Primary Progressive Multiple Sclerosis. Ann Neurol. 2021. PMID: 34590328. doi:10.1002/ana.26239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。